These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21114539)

  • 21. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
    Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
    Stühmer T; Iskandarov K; Gao Z; Bumm T; Grella E; Jensen MR; Einsele H; Chatterjee M; Bargou RC
    Anticancer Res; 2012 Feb; 32(2):453-62. PubMed ID: 22287732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein 90 as a drug target: some like it hot.
    Banerji U
    Clin Cancer Res; 2009 Jan; 15(1):9-14. PubMed ID: 19118027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
    Ocio EM; Mateos MV; Maiso P; Pandiella A; San-Miguel JF
    Lancet Oncol; 2008 Dec; 9(12):1157-65. PubMed ID: 19038762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat shock proteins in multiple myeloma.
    Zhang L; Fok JH; Davies FE
    Oncotarget; 2014 Mar; 5(5):1132-48. PubMed ID: 24675290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.
    Kolosenko I; Grander D; Tamm KP
    Curr Med Chem; 2014; 21(26):3042-7. PubMed ID: 24735367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hsp90: a novel target for cancer therapy.
    Solit DB; Rosen N
    Curr Top Med Chem; 2006; 6(11):1205-14. PubMed ID: 16842157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heat shock protein inhibitors and vaccines as new agents in cancer treatment.
    Karapanagiotou EM; Syrigos K; Saif MW
    Expert Opin Investig Drugs; 2009 Feb; 18(2):161-74. PubMed ID: 19236263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat shock proteins as a new, promising target of multiple myeloma therapy.
    Grosicki S; Bednarczyk M; Janikowska G
    Expert Rev Hematol; 2020 Feb; 13(2):117-126. PubMed ID: 31971027
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.
    Chatterjee S; Burns TF
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic targets for multiple myeloma.
    Mahindra A; Cirstea D; Raje N
    Future Oncol; 2010 Mar; 6(3):407-18. PubMed ID: 20222797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Untangling the unfolded protein response.
    Davenport EL; Morgan GJ; Davies FE
    Cell Cycle; 2008 Apr; 7(7):865-9. PubMed ID: 18414035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.
    Bruno B; Giaccone L; Rotta M; Anderson K; Boccadoro M
    Leukemia; 2005 Oct; 19(10):1729-38. PubMed ID: 16094421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in HSP27 and HSP90-targeting strategies for glioblastoma.
    van Ommeren R; Staudt MD; Xu H; Hebb MO
    J Neurooncol; 2016 Apr; 127(2):209-19. PubMed ID: 26842818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.